Phase 2 Safety and Efficacy Evaluation of AL8326 in ≥2nd Line SCLC

NCT ID: NCT05363280

Last Updated: 2025-09-23

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-11-01
• Study Completion Date: 2026-12-31

Brief Summary

This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC) patients who need ≥2nd line treatment .

Detailed Description

This study is designed for two steps: Phase 2 Optimal Biological Dose (OBD) finding and Phase 2 expansion cohort study after OBD determination.

The Phase 2 study aims to find optimal biological dose (OBD) initially. Patients will be randomized to 3 different dosing groups in OBD finding cohorts. Each cohort will enroll 6-12 SCLC patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage. This OBD finding cohort will also evaluate the pharmacokinetic profile of AL8326.

A phase 2 expansion cohort will be continued if a positive clinical result would have been observed after OBD determination for 40-60 patients. Upon FDA's approval the Phase 2 expansion cohort clinical study will be further expanded to evaluate the safety and efficacy of AL8326 in patients individually with SCLC who need = or >2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage.

Conditions

Small Cell Lung Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

OBD finding cohort at low dose

Subject in low dose group will receive AL8326 orally in each cycle until intolerable toxicity or disease progression or withdrawal . 6-12 subjects are in this group. Efficacy, safety and PK will be evaluated and compared within 3 different dosing group to define the final OBD.

Group Type: EXPERIMENTAL

AL8326 low dose group

Intervention Type: DRUG

Taken AL3826 at low dose orally

OBD finding cohort at middle dose

Subject in middle dose group will receive AL8326 orally in each cycle until intolerable toxicity or disease progression or withdrawal . 6-12 subjects are in this group. Efficacy, safety and PK will be evaluated and compared within 3 different dosing group to define the final OBD.

Group Type: EXPERIMENTAL

AL8326 middle dose group

Intervention Type: DRUG

Taken AL3826 at middle dose orally

OBD finding cohort at high dose

Subject in high dose group will receive AL8326 orally in each cycle until intolerable toxicity or disease progression or withdrawal . 6-12 subjects are in this group. Efficacy, safety and PK will be evaluated and compared within 3 different dosing group to define the final OBD.

Group Type: EXPERIMENTAL

AL8326 high dose group

Intervention Type: DRUG

Taken AL3826 at high dose orally

Interventions

AL8326 low dose group

Taken AL3826 at low dose orally

Intervention Type: DRUG

AL8326 middle dose group

Taken AL3826 at middle dose orally

Intervention Type: DRUG

AL8326 high dose group

Taken AL3826 at high dose orally

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or female, 18 years of age or older

2. ECOG performance status of 0 or 1

3. Histologically or cytologically confirmed SCLC

4. Have at least 1 lesion that meets the criteria for being measurable, as defined by RECIST 1.1

5. Have a life expectancy of at least 3 months

Exclusion Criteria

1. Serious, non-healing wound, ulcer or bone fracture

2. Major surgical procedure within 28 days or minor surgical procedure performed within 7 days prior to treatment

3. Active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels

4. Clinically significant cardiovascular disease including uncontrolled hypertension; myocardial infarction or unstable angina within 6 months prior to enrollment; New York Heart Association (NYHA) Grade II or greater congestive heart failure serious cardiac arrhythmia requiring medication; and Grade II or greater peripheral vascular disease

5. Hemoptysis within 3 months prior to enrollment

6. Concomitant treatment with strong inhibitors or inducers of CYP3A4, CYP2C9 and CYP2C19 within 14 days prior to enrollment and during the study unless there is an emergent or life-threatening medical condition that required it.

More information available upon request

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Advenchen Pharmaceuticals, LLC.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Saiama Waqar, MD

Role: PRINCIPAL_INVESTIGATOR

Washington University School of Medicine

Locations

University of Alabama at Birmingham

Birmingham, Alabama, United States

Northwestern University

Chicago, Illinois, United States

Siteman Cancer Center, Washington University

St Louis, Missouri, United States

Cleveland Clinic

Cleveland, Ohio, United States

Hospital Universitari Vall d'Hebron

Barcelona, , Spain

Hospital Universitario Ramón Y Cajal

Madrid, , Spain

Countries

United States; Spain

Other Identifiers

AL8326-US-001

Identifier Type: -

Identifier Source: org_study_id